Full-Time
Confirmed live in the last 24 hours
AI-driven healthcare data analysis platform
Senior
Company Historically Provides H1B Sponsorship
Boston, MA, USA
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, distinguishing itself through its focus on personalized medicine and extensive cancer research.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$894.9M
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.
Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.
Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression
Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).
Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.